Literature DB >> 19491062

Evidence-based medicine, clinical practice guidelines, and common sense in the management of osteoporosis.

E Michael Lewiecki1, Neil Binkley.   

Abstract

OBJECTIVE: To evaluate the benefits and limitations of randomized controlled trials (RCTs), clinical practice guidelines (CPGs), and clinical judgment in the management of osteoporosis.
METHODS: A review was conducted of the English-language literature on the origins and applications of RCTs, CPGs, evidence-based medicine, and clinical judgment in the management of osteoporosis.
RESULTS: Evidence-based medicine is use of the currently available best evidence in making clinical decisions for individual patients. CPGs are recommendations for making clinical decisions based on research evidence, sometimes with consideration of expert opinion, health care policy, and costs of care. The highest levels of medical evidence are usually thought to be RCTs and meta-analyses of high-quality RCTs. Although it is desirable and appropriate for clinicians to consider research evidence from RCTs and recommendations presented in CPGs in making clinical decisions, other factors-such as patient preference, comorbidities, affordability, and availability of care-are important for the actual implementation of evidence-based medicine.
CONCLUSION: Decisions about who to treat, which drug to use, how best to monitor, and how long to treat require clinical skills in addition to knowledge of medical research. The necessity of integrating common sense and clinical judgment is highlighted by the fact that many patients treated for osteoporosis in clinical practice would not qualify for participation in the pivotal clinical trials that demonstrated efficacy and safety of the drugs used to treat them.

Entities:  

Mesh:

Year:  2009        PMID: 19491062     DOI: 10.4158/EP09107.RA

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  6 in total

1.  Pituitary tumors: cabergoline versus bromocriptine: a meta-analysis?

Authors:  Mark E Molitch
Journal:  Nat Rev Endocrinol       Date:  2011-05       Impact factor: 43.330

2.  Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.

Authors:  Mohan Liu; Paul E Goss; James N Ingle; Michiaki Kubo; Yoichi Furukawa; Anthony Batzler; Gregory D Jenkins; Erin E Carlson; Yusuke Nakamura; Daniel J Schaid; Judy-Anne W Chapman; Lois E Shepherd; Matthew J Ellis; Sundeep Khosla; Liewei Wang; Richard M Weinshilboum
Journal:  Mol Endocrinol       Date:  2014-08-22

3.  Cellular senescence in bone.

Authors:  Joshua N Farr; Sundeep Khosla
Journal:  Bone       Date:  2019-01-16       Impact factor: 4.398

4.  "Evidence-based" or "logic-based" medicine?

Authors:  R D Blank; J P Bilezikian; S L Bonnick; A J Laster; E S Leib; E M Lewiecki; P D Miller; N B Watts; N Binkley
Journal:  Osteoporos Int       Date:  2010-05-13       Impact factor: 4.507

5.  Bisphosphonates for the treatment of osteoporosis: insights for clinicians.

Authors:  E Michael Lewiecki
Journal:  Ther Adv Chronic Dis       Date:  2010-05       Impact factor: 5.091

6.  Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis.

Authors:  N Freemantle; C Cooper; A Diez-Perez; M Gitlin; H Radcliffe; S Shepherd; C Roux
Journal:  Osteoporos Int       Date:  2012-07-26       Impact factor: 4.507

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.